España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Molecular Partners
MLLCF
OTCEM
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$4.22
Last update: Dec 31, 7:00 PM
Get Report
Comment
Molecular Partners (MLLCF) Forecast
News
Earnings
Molecular Partners (MLLCF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Molecular Partners (OTC:MLLCF) Stock
Molecular Partners Stock (OTC: MLLCF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, August 09, 2021
AbbVie Returns Eye Drug Candidate To Molecular Partners
Vandana Singh
Tuesday, July 13, 2021
Cowen Initiates Coverage On Molecular Partners With Price Target Of $50
Vandana Singh
Thursday, July 08, 2021
Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
Vandana Singh
Thursday, July 01, 2021
Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters
Vandana Singh
Thursday, May 27, 2021
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Shanthi Rexaline
Novartis, Molecular Partners Initiate Global Trial For COVID-19 Treatment
Vandana Singh
Tuesday, March 09, 2021
Molecular Partners/Novartis's COVID-19 Antiviral Therapy Shows Encouraging Action Early-Stage Study
Vandana Singh
Wednesday, October 28, 2020
Molecular Partners Announced Collaboration with Novartis to Develop two DARPin Therapies Designed for Potential Use against COVID-19
Charles Gross
Novartis Strikes Deal To Commercialize Molecular Partners' COVID-19 Drug Candidates
Shivdeep Dhaliwal
Friday, June 26, 2020
AbbVie Company Allergan and Molecular Partners Receive CRL from FDA on Biologics License Application for Abicipar pegol
Charles Gross
Friday, October 04, 2019
Allergan Partner Molecular Partners Announces Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting
Charles Gross
Wednesday, December 19, 2018
Amgen, Molecular Partners Announce Strategic Collaboration In Immuno-Oncology; Molecular Partners to Receive $50M Upfront; Up to $497M in Milestones
Charles Gross
